MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer
- Submitting institution
-
The University of Westminster
- Unit of assessment
- 11 - Computer Science and Informatics
- Output identifier
- q3530
- Type
- D - Journal article
- DOI
-
10.1038/bjc.2017.387
- Title of journal
- British Journal of Cancer
- Article number
- -
- First page
- 258
- Volume
- 118
- Issue
- 2
- ISSN
- 0007-0920
- Open access status
- Compliant
- Month of publication
- November
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- 3 - Allied Health Professions, Dentistry, Nursing and Pharmacy
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
12
- Research group(s)
-
-
- Citation count
- 22
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- It is hypothesised that the glutamine–proline regulatory axis has a key role in breast cancer in the highly proliferative classes and that this pathway could be used as a potential therapeutic target. This work is significant, because it shows that cluster analysis of the glutamine–proline regulatory axis genes can be efficiently used to reveal significant associations with molecular subtypes of breast cancer and patient outcome independent of standard clinicopathological parameters. It also demonstrates that the glutamine–proline regulatory axis plays an important role in the aggressive subclass of luminal breast cancer and is therefore a potential therapeutic target.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
